A retrospective analysis of the safety profile of intravenous immunoglobulin in 1176 patients receiving home infusion therapy

Nizar Souayah, Ankit Pahwa, Lauren Burawski, Tamara Opila, Howard W. Sander

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives: This analysis assessed the safety of intravenous immunoglobulin (IVIg) in the treatment of patients with neuroimmunological and immunological disorders in a home-based setting. Methods: Adverse reactions (ARs) were assessed in a retrospective review of 1176 patients receiving 28,677 home-based IVIg infusions between 1996 and 2013. Results: Of 1176 patients, 648 (55.1%) experienced IVIgrelated ARs; 536 (45.6%) were mild, 78 (6.6%) moderate, and 34 (2.9%) severe. Thirty-seven (3.1%) patients were hospitalized because of ARs; of these, headache was most common (51.4%). Mean number of ARs per patient increased from 1.4 (low dose) to 3.6 (high dose). Incidence of ARs increased from 41% in the first 5-year moving average in 2003 to 65% in 2008. The number of ARs correlated with the number of infusions (r =0.24; P < 0.001) and the average IVIg dose (r =0.10; P < 0.001). Conclusions: Low- and high-dose IVIg were safe and well tolerated with a few serious ARs in patients with neuroimmunological and immunological disorders.

Original languageEnglish (US)
Pages (from-to)181-195
Number of pages15
JournalJournal of clinical neuromuscular disease
Volume19
Issue number4
DOIs
StatePublished - 2018

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Keywords

  • Home infusion
  • IVIg
  • Immunological
  • Neuroimmunological
  • Neuromuscular

Fingerprint

Dive into the research topics of 'A retrospective analysis of the safety profile of intravenous immunoglobulin in 1176 patients receiving home infusion therapy'. Together they form a unique fingerprint.

Cite this